Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,506.00
(
0.28%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
92.82
(
1.59%
)
Bitcoin
73,833.50
(
0.38%
)
News Focus
News Focus
Post# of 518980
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Doc328

Send PM Follow Ignore
Followers 75
Posts 2595
Boards Moderated 0
Alias Born 03/04/2018

Doc328

Re: boi568 post# 333718

Monday, 10/25/2021 12:38:11 PM

Monday, October 25, 2021 12:38:11 PM

Post# of 518980
I doubt there will be a Rett gene therapy on the market before 2026 so if the Excellence study looks good and they can send in an NDA by the end of 2022, Anavex would not have to worry about gene therapy competition for a few years.

There are some parallels with Spinraza for SMA and Zolgensa (gene therapy)
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News